FOR investors, impact & ROI need not be mutually exclusive

THE OPPORTUNITY

THE IMPACT

THE PORTFOLIO

The Opportunity

Millions of individuals are affected by ASD, neurodevelopmental disorders (NDDs), and mental health conditions worldwide. 

ASD

1 in 44

Children receive an ASD diagnosis

NDD

1 in 7

Children have a neurodevelopmental disorder

MENTAL HEALTH

1 in 5

Individuals have a mental health condition

In the U.S. alone, 5.4 million individuals have received an ASD diagnosis, 11 million children have a NDD, and 66 million individuals have a mental health condition.

For reasons that are not entirely understood, prevalence of these conditions is increasing exponentially, with no signs of slowing down. Of note, ASD prevalence has increased 241% over the past two decades. 

A favorable regulatory climate has made obtaining coverage for the diagnosis, treatment, and management of these conditions more accessible. 

However, there are still limited diagnostic, therapeutic, and service-oriented options for affected individuals and their families. 

As a result, stakeholders are left to cope with long wait times, ineffective treatments, and a fragmented care system.

At AIF, we are tapping a ~$800 billion market, directing capital toward companies that are transforming how ASD, NDDs, mental health issues, and other complex chronic conditions are diagnosed, treated, and managed. 

By investing in innovative life sciences and tech- and data-enabled services companies, we are using venture capital investment as a vehicle for deepening understanding, establishing a better standard of care, and enabling the individuals (and their families) affected by these conditions to reach their full potential. 

ANNUAL HEALTHCARE EXPENDITURE (U.S.)

$ 300 B
annual spend on ASD (U.S.)
$ 225 b
annual spend on NDDs (excludes ASD) (U.S.)
$ 175 b
annual spend on mental health (U.S.)
$ 775 B
addressable market (U.S.)

The Impact

At AIF, we hold ourselves accountable to the millions of people worldwide affected by ASD, NDDs, mental health issues, and other complex chronic conditions.

We invest in critically unmet healthcare needs affecting the ASD, NDD, and mental health communities across the life sciences and tech- and data-enabled services. 

We are building a portfolio that addresses comprehensive care for this population, supporting the community from early childhood through adulthood.

We identify passionate founders who are addressing pain points head-on, and work with them to develop sustainable business models that will yield returns for both the community and investors. 

Through our ecosystem approach of investing, we seek to cultivate a collaborative network of portfolio companies, corporate partners, nonprofits, academic institutions, and families to drive transformative innovation in this sector. 

Impact Goals

1

Expedite the diagnostic process. 

2

Define conditions with precision.  

3

Identify quantifiable biomarkers. 

4

Integrate data across patients, providers and platforms. 

5

AI x ASD

Leverage the power of AI.

6

Develop safe treatments for core symptoms. 

7

ASD+

Alleviate comorbidities.

8

Create quality, lifelong educational tools.

9

Support autistic individuals in achieving independence.

10

Provide a path to financial security. 

11

Democratize access to care. 

12

Foster innovative partnerships. 

FOR investors, impact & ROI need not be mutually exclusive

THE OPPORTUNITY

THE IMPACT

THE PORTFOLIO

The Opportunity

Millions of individuals are affected by ASD, neurodevelopmental disorders (NDDs), and mental health conditions worldwide. 

ASD

1 in 44

Children receive an ASD diagnosis

NDD

1 in 7

Children have a neurodevelopmental disorder

MENTAL HEALTH

1 in 5

Individuals have a mental health condition

In the U.S. alone, 5.4 million individuals have received an ASD diagnosis, 11 million children have a NDD, and 66 million individuals have a mental health condition.

For reasons that are not entirely understood, prevalence of these conditions is increasing exponentially, with no signs of slowing down. Of note, ASD prevalence has increased 241% over the past two decades. 

A favorable regulatory climate has made obtaining coverage for the diagnosis, treatment, and management of these conditions more accessible. 

However, there are still limited diagnostic, therapeutic, and service-oriented options for affected individuals and their families. 

As a result, stakeholders are left to cope with long wait times, ineffective treatments, and a fragmented care system.

At AIF, we are tapping a ~$1.2 trillion market, directing capital toward companies that are transforming how ASD, NDDs, mental health issues, and other complex chronic conditions are diagnosed, treated, and managed. 

By investing in innovative life sciences and tech- and data-enabled services companies, we are using venture capital investment as a vehicle for deepening understanding, establishing a better standard of care, and enabling the individuals (and their families) affected by these conditions to reach their full potential. 

National Healthcare Expenditure (U.S.)

$ 300 B
annual spend on ASD (U.S.)
$ 575 b
annual spend on NDDs (U.S.)
$ 175 b
annual spend on mental health (U.S.)
$ 0.1 T
addressable market (U.S.)

The Impact

At AIF, we hold ourselves accountable to the millions of people worldwide affected by ASD, NDDs, mental health issues, and other complex chronic conditions.

We invest in critically unmet healthcare needs affecting the ASD, NDD, and mental health communities across the life sciences and tech- and data-enabled services. 

We are building a portfolio that addresses comprehensive care for this population, supporting the community from early childhood through adulthood.

We identify passionate founders who are addressing pain points head-on, and work with them to develop sustainable business models that will yield returns for both the community and investors. 

Through our ecosystem approach of investing, we seek to cultivate a collaborative network of portfolio companies, corporate partners, nonprofits, academic institutions, and families to drive transformative innovation in this sector. 

Impact Goals

1

Expedite the diagnostic process. 

2

Define conditions with precision.  

3

Identify quantifiable biomarkers. 

4

Integrate data across patients, providers and platforms. 

5

AI x ASD

Leverage the power of AI.

6

Develop safe treatments for core symptoms. 

7

ASD+

Alleviate comorbidities.

8

Create quality, lifelong educational tools.

9

Support autistic individuals in achieving independence.

10

Provide a path to financial security. 

11

Democratize access to care. 

12

Foster innovative partnerships. 

1 in 54 children are diagnosed with autism, with 5.4 million autistic individuals in the U.S. Despite growing spending on autism, there are still limited diagnostic, therapeutic, and service-oriented options for autistic individuals and their families. As a result, stakeholders are left to cope with long wait times, ineffective treatments, and a fragmented care system.

 

Given a favorable regulatory climate which now requires that payers in all 50 U.S. states provide coverage for ASD diagnosis, treatment, and services, families have an increased ability to access impactful interventions. 

 

At AIF, we are directing capital toward companies that are transforming how autism is diagnosed, treated, and managed. 

 

By investing in early-stage life sciences and life span services companies, we are using venture capital investment as a vehicle for deepening our understanding of autism, establishing a better standard of care, and enabling autistic individuals to reach their full potential. 

Autism Spending in the U.S.

$ 20 k
personal cost of care annually
$ 300 b
spent on ASD annually
0 %
average annual increase in payer spend
in the last 5 years

Millions of individuals are affected by ASD, neurodevelopmental disorders (NDDs), and mental health conditions worldwide. 

In the U.S. alone, 5.4 million individuals have received an ASD diagnosis, 11 million children have a NDD, and 66 million individuals have a mental health condition.

For reasons that are not entirely understood, prevalence of these conditions is increasing exponentially, with no signs of slowing down. Of note, ASD prevalence has increased 241% over the past two decades. 

A favorable regulatory climate has made obtaining coverage for the diagnosis, treatment, and management of these conditions more accessible. 

However, there are still limited diagnostic, therapeutic, and service-oriented options for affected individuals and their families. As a result, stakeholders are left to cope with long wait times, ineffective treatments, and a fragmented care system.

At AIF, we are tapping a ~$1.2 trillion market, directing capital toward companies that are transforming how ASD, NDDs, mental health issues, and other complex chronic conditions are diagnosed, treated, and managed. 

By investing in innovative life sciences and tech- and data-enabled services companies, we are using venture capital investment as a vehicle for deepening understanding, establishing a better standard of care, and enabling the individuals (and their families) affected by these conditions to reach their full potential. 

National Healthcare Expenditure (U.S.)

$ 300 B
annual spend on ASD (U.S.)
$ 575 b
annual spend on NDDs (U.S.)
$ 175 b
annual spend on mental health (U.S.)
$ 0.1 T
addressable market (U.S.)